These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29801053)

  • 41. Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy.
    Cremers CH; Fischer MJ; Kruitwagen-van Reenen ET; Wadman RI; Vervoordeldonk JJ; Verhoef M; Visser-Meily JM; van der Pol WL; Schröder CD
    Neuromuscul Disord; 2019 Apr; 29(4):321-329. PubMed ID: 30954388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic nature of spinal muscular atrophy revealed by studying insurance claims.
    Lipnick SL; Agniel DM; Aggarwal R; Makhortova NR; Finlayson SG; Brocato A; Palmer N; Darras BT; Kohane I; Rubin LL
    PLoS One; 2019; 14(3):e0213680. PubMed ID: 30870495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variations in prenatal screening in a US federal healthcare system: Same coverage, different options.
    Thagard AS; Foglia LM; Staat BC; Lutgendorf MA
    J Genet Couns; 2019 Dec; 28(6):1148-1153. PubMed ID: 31538382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spinal muscular atrophy: A modifiable disease emerges.
    Fitzgerald DA; Abel F; Jones KJ; Farrar MA
    Paediatr Respir Rev; 2018 Sep; 28():1-2. PubMed ID: 30414816
    [No Abstract]   [Full Text] [Related]  

  • 45. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
    Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
    Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
    Thokala P; Stevenson M; Kumar VM; Ren S; Ellis AG; Chapman RH
    Cost Eff Resour Alloc; 2020; 18():41. PubMed ID: 33041673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes.
    Waldrop MA; Karingada C; Storey MA; Powers B; Iammarino MA; Miller NF; Alfano LN; Noritz G; Rossman I; Ginsberg M; Mosher KA; Broomall E; Goldstein J; Bass N; Lowes LP; Tsao CY; Mendell JR; Connolly AM
    Pediatrics; 2020 Sep; 146(3):. PubMed ID: 32843442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
    Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
    Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.
    Hoot NR
    Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31506303
    [No Abstract]   [Full Text] [Related]  

  • 51. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
    Al-Zaidy SA; Kolb SJ; Lowes L; Alfano LN; Shell R; Church KR; Nagendran S; Sproule DM; Feltner DE; Wells C; Ogrinc F; Menier M; L'Italien J; Arnold WD; Kissel JT; Kaspar BK; Mendell JR
    J Neuromuscul Dis; 2019; 6(3):307-317. PubMed ID: 31381526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Programmed cell death and the gene behind spinal muscular atrophy.
    Robinson A
    CMAJ; 1995 Nov; 153(10):1459-62. PubMed ID: 7585374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe.
    Peña-Longobardo LM; Aranda-Reneo I; Oliva-Moreno J; Litzkendorf S; Durand-Zaleski I; Tizzano E; López-Bastida J
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32764338
    [No Abstract]   [Full Text] [Related]  

  • 57. Infantile spinal muscular atrophy - the potential for cure of a fatal disease.
    Volpe JJ
    J Neonatal Perinatal Med; 2021; 14(2):153-157. PubMed ID: 33459670
    [No Abstract]   [Full Text] [Related]  

  • 58. Overexpression of SMN2 Gene in Motoneuron-Like Cells Differentiated from Adipose-Derived Mesenchymal Stem Cells by Ponasterone A.
    Mohseni R; Ashrafi MR; Ai J; Nikougoftar M; Mohammadi M; Ghahvechi-Akbari M; Shoae-Hassani A; Hamidieh AA
    J Mol Neurosci; 2019 Feb; 67(2):247-257. PubMed ID: 30535775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.
    Richardson RC
    JAMA Pediatr; 2018 Jul; 172(7):701. PubMed ID: 29801053
    [No Abstract]   [Full Text] [Related]  

  • 60. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.
    Prasad V
    JAMA Pediatr; 2018 Jul; 172(7):701-702. PubMed ID: 29800980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.